As we aim at clinical applications, we focus on the full system functionality with cell numbers that are relevant for the clinical use. We will optimize our system and the functional protocols to prove efficient use with small samples. We plan, at the end of the project, to transfer our droplet microfluidic platform in clinical setting. Tumor biopsies and peripheral blood from patients with lung or colorectal cancer will be obtained from the Biobank of the DO. Relevant potential neo-antigens and other tumor antigens will be determined using our comprehensive multi-omics algorithm, while TILs will be derived and expanded. The tumor-reactive cells isolated using the droplet microfluidic platform will be isolated and expanded using the established standard operating procedures from the cell manufacturing facility (CMF-GMP) in order to validate the generation of clinical-grade tumor-specific T cells for personalized immunotherapy (ACT).